Available Clinical Trials at Pacific Cancer Care
Pacific Cancer Care is driven by a vision to be the leader for the treatment of cancer in the Monterey County. Our clinicians and investigators identify and conduct Phase I-IV treatment options that are new and innovative, and that will positively impact our patients. Below is a list of clinical trials currently available at Pacific Cancer Care.
For more information regarding clinical trial opportunities, please contact us at (831) 375-4105.
Solid Tumor and Hematologic Malignancies
Protocol Number: Patient-centered Outcomes Research Institute Study – Stanford – 63775
Protocol Title: Comparative Effectiveness Trial of Two Supportive Cancer Care Delivery Models for Adults with Cancer
More Information available at: https://clinicaltrials.gov/ct2/show/NCT05297734
Eligibility criteria:
- Newly diagnosed cancer patients or recurrence of disease
- Must be 21 years or older
- Ability to understand and willing to provide informed consent
- Speak English or Spanish
Ineligibility criteria:
- Inability to consent to the study
- Plans to change their oncologist within 12 months
- Employed by the practice site
- Patients who anticipate moving away from the area within 12 months
Breast Cancer
Protocol Number: MK3475-B49
Protocol Title: A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of Pembrolizumab Plus Chemotherapy Versus Placebo Plus Chemotherapy for the Treatment of Chemotherapy-Candidate Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative (HR+/HER2-) Locally Recurrent Inoperable or Metastatic Breast Cancer (KEYNOTE-B49)
More information available at: https://clinicaltrials.gov/ct2/show/NCT04895358
Hematologic Malignancies
Protocol Number: MK-4280-003
Protocol Title: A Phase 1/Phase 2 Clinical Study to Evaluate the Safety and Efficacy of a Combination of MK-4280 and Pembrolizumab (MK-3475) in Participants With Hematologic Malignancies
More information available at: https://clinicaltrials.gov/ct2/show/NCT03598608
Ovarian Cancer
Protocol Number: MK-3475-B96
Protocol Title: A Phase 3, Randomized, Double-Blind Study of Pembrolizumab versus Placebo in Combination with Paclitaxel With or Without Bevacizumab for the Treatment of Platinum-resistant Recurrent Ovarian Cancer (KEYNOTE B-96/ ENGOT-ov65)
More information available at: https://www.clinicaltrials.gov/ct2/show/NCT05116189